Literature DB >> 24966896

miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.

Pablo Letelier1, Patricia García2, Pamela Leal3, Héctor Álvarez4, Carmen Ili3, Jaime López3, Jonathan Castillo3, Priscilla Brebi3, Juan Carlos Roa2.   

Abstract

The development of miRNA-based therapeutics represents a new strategy in cancer treatment. The objectives of this study were to evaluate the differential expression of microRNAs in gallbladder cancer (GBC) and to assess the functional role of miR-1 and miR-145 in GBC cell behavior. A profile of miRNA expression was determined using DharmaconTM microarray technology. Differential expression of five microRNAs was validated by TaqMan reverse transcription quantitative-PCR in a separate cohort of 8 tumors and 3 non-cancerous samples. Then, we explored the functional role of miR-1 and miR-145 in tumor cell behavior by ectopic in vitro expression in the GBC NOZ cell line. Several miRNAs were found to be aberrantly expressed in GBC; most of these showed a significantly decreased expression compared to non-neoplastic tissues (Q value<0.05). The differential expression of 7 selected miRNAs was confirmed by real time PCR. Pathway enrichment analysis revealed that the most deregulated miRNAs (miR-1, miR-133, miR-143 and miR-145) collectively targeted a number of genes belonging to signaling pathways such as TGF-β, ErbB3, WNT and VEGF, and those regulating cell motility or adhesion. The ectopic expression of miR-1 and miR-145 in NOZ cells significantly inhibited cell viability and colony formation (P<0.01) and reduced gene expression of VEGF-A and AXL. This study represents the first investigation of the miRNA expression profile in gallbladder cancer, and our findings showed that several miRNAs are deregulated in this neoplasm. In vitro functional assays suggest that miR-1 and miR-145 act as tumor suppressor microRNAs in GBC.

Entities:  

Keywords:  Gallbladder cancer; NOZ cells; miR-1; miR-145; microRNAs

Mesh:

Substances:

Year:  2014        PMID: 24966896      PMCID: PMC4069933     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  91 in total

1.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

2.  Downregulation of microRNA-200 in EBV-associated gastric carcinoma.

Authors:  Aya Shinozaki; Takashi Sakatani; Tetsuo Ushiku; Rumi Hino; Maya Isogai; Shunpei Ishikawa; Hiroshi Uozaki; Kenzo Takada; Masashi Fukayama
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

3.  The functional significance of miR-1 and miR-133a in renal cell carcinoma.

Authors:  Kazumori Kawakami; Hideki Enokida; Takeshi Chiyomaru; Shuichi Tatarano; Hirofumi Yoshino; Ichiro Kagara; Takenari Gotanda; Tokushi Tachiwada; Kenryu Nishiyama; Nijiro Nohata; Naohiko Seki; Masayuki Nakagawa
Journal:  Eur J Cancer       Date:  2012-04       Impact factor: 9.162

4.  Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling.

Authors:  Violaine Havelange; Nicole Stauffer; Catherine C E Heaphy; Stefano Volinia; Michael Andreeff; Guido Marcucci; Carlo M Croce; Ramiro Garzon
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

5.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

Review 6.  The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.

Authors:  Hiroyuki Takahashi; Masabumi Shibuya
Journal:  Clin Sci (Lond)       Date:  2005-09       Impact factor: 6.124

7.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

Review 8.  Vascular endothelial growth factor as a target for anticancer therapy.

Authors:  Napoleone Ferrara
Journal:  Oncologist       Date:  2004

9.  MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.

Authors:  Fernando Colbari Amaral; Natalia Torres; Fabiano Saggioro; Luciano Neder; Hélio Rubens Machado; Wilson Araújo Silva; Ayrton Custódio Moreira; Margaret Castro
Journal:  J Clin Endocrinol Metab       Date:  2008-10-07       Impact factor: 5.958

10.  Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.

Authors:  S Kojima; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; N Nohata; M Fuse; T Ichikawa; Y Naya; M Nakagawa; N Seki
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

View more
  41 in total

1.  Expression of TGF-β1 and miRNA-145 in patients with diabetic foot ulcers.

Authors:  Fengmei Zhang; Yuguo Ren; Peng Liu; Yufeng Ren; Debao Wang
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

2.  A rare case report of chronic cholecystitis complicated with incomplete gallbladder volvulus.

Authors:  P Luo; Cm Wang; Gx Zhang
Journal:  Int J Clin Exp Med       Date:  2014-10-15

3.  Exploration of the regulation and control mechanisms of miR-145 in trophoblast cell proliferation and invasion.

Authors:  Zhenjing Chi; Muling Zhang
Journal:  Exp Ther Med       Date:  2018-10-23       Impact factor: 2.447

4.  MicroRNA-133a-3p exerts inhibitory effects on gallbladder carcinoma via targeting RBPJ.

Authors:  Yuan Huang; Yaoshi Wu; Jiahong Dong; Dongdong Han; Shiwei Yang; Lin Jiang
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

5.  miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.

Authors:  Ming Zhan; Xiaonan Zhao; Hui Wang; Wei Chen; Sunwang Xu; Wei Wang; Hui Shen; Shuai Huang; Jian Wang
Journal:  Tumour Biol       Date:  2016-02-08

6.  miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma.

Authors:  Xi Chen; Jingxuan Shi; Jianwen Zhong; Zhenyun Huang; Xi Luo; Yaping Huang; Shuang Feng; Jianbo Shao; Dabo Liu
Journal:  Int J Exp Pathol       Date:  2016-01-19       Impact factor: 1.925

Review 7.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 8.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26

9.  The role of microRNAs in gallbladder cancer.

Authors:  Ganghua Yang; Lei Zhang; Ruixiang Li; Lin Wang
Journal:  Mol Clin Oncol       Date:  2016-05-11

10.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.